POPULARITY
11 episodes with clinical decision making
6 episodes with clinical decision making
7 episodes with clinical decision making
10 episodes with clinical decision making
7 episodes with clinical decision making
3 episodes with clinical decision making
4 episodes with clinical decision making
4 episodes with clinical decision making
4 episodes with clinical decision making
On a cold January day in South Carolina, Jamie and Matt Staub unpack why focus is one of the most underrated leadership skills—especially in healthcare, where everything can feel urgent. They break down how leaders decide what deserves attention, how to “push pause” on non-emergencies, and why coaching people through problems is often more effective than absorbing them. The conversation also explores decision fatigue, the difference between being busy and being focused, the role of habits (including insights from Atomic Habits), and how boundaries protect the work that actually moves the mission forward. Along the way, they normalize attention struggles, reframe “failure” as part of growth, and offer practical ways to stay aligned to goals without losing empathy or accessibility.
Join Elevated GP: www.theelevatedgp.com Register for the live meeting: https://www.theelevatedgp.com/ElevationSummit Download the Injection Molding Guide: https://www.theelevatedgp.com/IMpdf Episode Description In part two of this in-depth conversation, Dr. John Kois moves beyond theory and into clinical application, tackling the questions every restorative dentist eventually faces: Who is actually a high-risk occlusal patient? How do we distinguish past adaptation from active breakdown? And why do so many "standard solutions" fail to prevent restorative complications? Building on the foundational concepts from part one, this episode focuses on how occlusion shows up in day-to-day practice—and how dentists can make more informed decisions before committing to complex restorative or implant treatment. Dr. Kois explains why visual wear alone is an unreliable predictor of risk, how to identify whether wear is active versus inactive, and why patient symptoms often tell a more important story than what we see on models or scans. A major theme of this conversation is closing the gap between chairside evaluation and real-world function. Dr. Kois challenges common habits—such as adjusting restorations with patients fully reclined, relying solely on articulating paper marks, or reflexively prescribing nightguards—and explains why these approaches often miss the true etiology of failure. Instead, he emphasizes evaluating occlusion in positions and movements that reflect how patients actually chew, speak, and function throughout the day. In this episode, you'll learn: How to identify true high-risk occlusal cases before restorative treatment begins Why active wear and patient-reported change matter more than historical attrition How muscle symptoms, mobility, and joint loading influence predictability When nightguards and Botox may mask symptoms rather than solve the problem Why larger restorative and implant cases demand a deeper understanding of jaw position, tooth fit, and functional pathways Dr. Kois also shares candid insights on emerging technologies such as jaw tracking—where they add value, where they fall short, and why they are most impactful in comprehensive and full-arch cases rather than routine dentistry. The discussion highlights an important truth: many restorative failures are not material failures, but diagnostic failures rooted in incomplete occlusal assessment. The episode closes with a powerful reflection on learning, clinical growth, and professional development—distinguishing information from knowledge, and knowledge from wisdom. Dr. Kois outlines the progression from skepticism to commitment, underscoring why true clinical mastery requires not just understanding concepts, but applying them consistently over time. Together, parts one and two form a cohesive framework for thinking differently about occlusion—one grounded in physiology, adaptation, and long-term predictability. If you're aiming to move beyond bread-and-butter dentistry and into more complex, fulfilling clinical work, this conversation provides essential perspective on how to do so more thoughtfully and successfully.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/GKD865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Redrawing Frontlines in MCL: The Upfront Expansion of BTKi Options & Modern Clinical Decision-making in Newly Diagnosed Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Mantle Cell Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
In this episode, Solomon Moshkevich, president of clinical diagnostics at Natera, discusses how molecular data, MRD testing, and AI-driven tools are transforming clinical decision making across oncology, prenatal care, and chronic kidney disease. He shares insights on evidence generation, system integration, and the opportunities ahead for more personalized, cost-effective care.This episode is sponsored by Natera.
What if you could transform the future of military medicine with the power of AI and technology? Join us for a captivating conversation with retired Navy Master Chief and Independent Duty Corpsman Joe Espinosa, who takes us through his remarkable journey in military healthcare. From his early days navigating the austere environments with the 2nd Battalion, 1st Marines, to becoming a strategic leader shaping the hospital corps, Joe offers invaluable lessons on adaptability, preparation, and the critical balance between clinical confidence and humility. Listen as Master Chief Espinosa shares his pivotal experiences on smaller Navy ships and the USS Stockdale, where he honed skills in resource management and prioritization—an essential foundation for his role as Force Medical Master Chief. His insights into leadership are enriched by real-world frontline experiences, underscoring the vitality of robust support systems for those serving in combat zones. A decisive encounter with a Master Chief mentor propelled Joe into a leadership role, ultimately guiding the strategic direction of the corpsman community and championing the integration of healthcare technology with T6 Health Systems. Explore the future of military healthcare as Joe discusses the integration of AI and predictive logistics to enhance decision-making and improve survivability in the most critical situations. Delve into the innovative developments aiming to address communication challenges in deployed healthcare systems and the seamless integration of technologies like MHS Genesis. With an emphasis on how emerging tools can support the military's medical personnel, this episode serves as a beacon for understanding the evolving landscape of military medicine and the pivotal role technology plays in shaping its future. Chapters: (00:04) Master Chief Espinosa's Path in Military Medicine (11:58) Healthcare Leadership and Strategic Planning (20:58) Transition and Future of Military Medicine (29:51) Future of Military Healthcare Communication (35:41) Software Development and Military Healthcare (40:23) AI Integration in Military Healthcare (45:17) Future Developments and Challenges in Military Healthcare Chapter Summaries: (00:04) Master Chief Espinosa's Path in Military Medicine Retired Navy Master Chief Joe Espinosa shares his journey in military medicine, emphasizing mentorship and the need for innovation and technology. (11:58) Healthcare Leadership and Strategic Planning Transition from smaller to larger ships, managing medical supplies, frontline experiences, unexpected path to leadership. (20:58) Transition and Future of Military Medicine Enlisted voices shape military medical systems and face challenges transitioning to civilian life, but can use leadership skills in new roles. (29:51) Future of Military Healthcare Communication Improving communication in deployed military healthcare systems with bi-directional feedback and innovative solutions like animated QR codes. (35:41) Software Development and Military Healthcare MHS Genesis integrates with other systems, ensuring seamless transfer of healthcare records for veterans in military and VA services. (40:23) AI Integration in Military Healthcare Technology and healthcare intersect in military and civilian settings, with AI and wearables aiding decision-making for medical personnel. (45:17) Future Developments in Military Healthcare The role of technology in healthcare, predictive logistics for medical supply management, and transitioning from military to civilian healthcare technology. Balancing functionality and resource efficiency in military healthcare through agile development and user feedback. Take Home Messages: Intersection of Military Medicine and Technology: The episode explores the transformative impact of technology on military medicine, highlighting how advancements like AI and predictive logistics are revolutionizing communication and decision-making in challenging environments. This integration empowers medical personnel, especially junior corpsmen, to enhance their clinical decision-making and improve patient outcomes. Mentorship and Leadership Development: Emphasizing the importance of mentorship, the episode discusses how strategic planning and resource management are vital for effective healthcare leadership. Experiences from frontline medical roles significantly shape leaders, underscoring the need for adaptability and open communication within the military healthcare system. Navigating Career Transitions: Transitioning from a military to a civilian career can be challenging. The episode offers insights into recognizing the value of leadership and problem-solving skills gained in the military and encourages an open-minded approach to exploring diverse career opportunities beyond traditional paths. Improving Healthcare Communication: Addressing longstanding communication challenges in deployed settings, the episode discusses innovative solutions like bi-directional communication systems and animated QR codes that ensure seamless information transfer, enhancing the overall experience for medical personnel and patients in disconnected environments. Future of Military Healthcare: The episode envisions a future where technology, including mobile devices and AI, plays a crucial role in healthcare delivery. It discusses the potential for real-time data capture and analysis to alleviate cognitive burdens on healthcare providers, fostering confidence and improving decision-making in critical situations. Episode Keywords: Military medicine, healthcare innovation, AI integration, Joe Espinosa, War Docs podcast, frontline experiences, medical leadership, T6 Health Systems, predictive logistics, healthcare technology, Navy Master Chief, mentorship in healthcare, medical department setup, medical resource management, communication in healthcare, AI in military medicine, clinical decision support, military healthcare systems, medical mentorship, operational medicine Hashtags: #MilitaryMedicine #AIinHealthcare #HealthcareInnovation #FrontlineMedicine #JoeEspinosa #MentorshipInMedicine #WarDocsPodcast #PredictiveLogistics #MedicalLeadership #HealthcareTechnology **This Episode was supported by an Educational Grant from one of our WarDocs Sponsors- T6 Health Systems** Honoring the Legacy and Preserving the History of Military Medicine The WarDocs Mission is to honor the legacy, preserve the oral history, and showcase career opportunities, unique expeditionary experiences, and achievements of Military Medicine. We foster patriotism and pride in Who we are, What we do, and, most importantly, How we serve Our Patients, the DoD, and Our Nation. Find out more and join Team WarDocs at https://www.wardocspodcast.com/ Check our list of previous guest episodes at https://www.wardocspodcast.com/our-guests Subscribe and Like our Videos on our YouTube Channel: https://www.youtube.com/@wardocspodcast Listen to the “What We Are For” Episode 47. https://bit.ly/3r87Afm WarDocs- The Military Medicine Podcast is a Non-Profit, Tax-exempt-501(c)(3) Veteran Run Organization run by volunteers. All donations are tax-deductible and go to honoring and preserving the history, experiences, successes, and lessons learned in Military Medicine. A tax receipt will be sent to you. WARDOCS documents the experiences, contributions, and innovations of all military medicine Services, ranks, and Corps who are affectionately called "Docs" as a sign of respect, trust, and confidence on and off the battlefield,demonstrating dedication to the medical care of fellow comrades in arms. Follow Us on Social Media Twitter: @wardocspodcast Facebook: WarDocs Podcast Instagram: @wardocspodcast LinkedIn: WarDocs-The Military Medicine Podcast YouTube Channel: https://www.youtube.com/@wardocspodcast
Nicholas C Spies, Embracing Generative Artificial Intelligence as a Support Tool for Clinical Decision-Making, Clinical Chemistry, Volume 71, Issue 11, November 2025, Pages 1178–1179, https://doi.org/10.1093/clinchem/hvaf084
Our 52nd episode of QuidelOrtho Science Bytes features George Wierschem, Senior Global Product Manager – informatics, discussing how informatics is transforming clinical labs. From streamlining workflows to strengthening cybersecurity, informatics helps labs turn data into decisions – faster, smarter and more securely. George shares how modern platforms improve lab efficiency, ensure data integrity and support better patient outcomes through centralized access, automation and accountability. About Our Speaker: George Wierschem Senior Global Product Manager for informatics at QuidelOrtho George is a trained medical technologist with more than 30 years of laboratory experience. Over the first half of his career, George worked in a number of community-based hospitals progressing from bench technologist into leadership positions. In 2010, George entered the in vitro diagnostics industry, where he's been able to leverage his strong laboratory experience in consulting, product development and product management roles. Currently, George is helping to support legacy QuidelOrtho informatics platforms while also developing several innovative next-generation solutions. George holds an MBA with a healthcare administration specialization and is certified in Lean Six Sigma and change management.
CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
In this episode, Dr. Sandra Pagenta, DNP APRN interviews Dr. Anne Meneghetti, an MD and physician executive at Epocrates, discussing her journey in medicine and the impact of the Epocrates app on clinical practice. They explore the app's features, its role in reducing medical errors, and how it supports nurse practitioners in making informed decisions at the point of care. The conversation also touches on the importance of patient education, the shift towards individualized care, and the future of technology in healthcare.Anne Meneghetti, MD: https://www.linkedin.com/in/anne-meneghetti-395504195/Check out Epocrates: https://www.epocrates.com/ CODE: SUCCESSTDC Group Live Webinar Link: https://registration.socio.events/e/apcriskCheck out our eBooks designed specifically for NP students navigating the clinical setting! https://bit.ly/SuccessNPebookFollow us on instagram: @thesuccesnpGo to our website www.successnps.com
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EPE865. CME credit will be available until September 16, 2026.Mastering Cannabinoid Science: Key Insights for Informed Clinical Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EPE865. CME credit will be available until September 16, 2026.Mastering Cannabinoid Science: Key Insights for Informed Clinical Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EPE865. CME credit will be available until September 16, 2026.Mastering Cannabinoid Science: Key Insights for Informed Clinical Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EPE865. CME credit will be available until September 16, 2026.Mastering Cannabinoid Science: Key Insights for Informed Clinical Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
In today's episode, we spoke with Scott Kopetz, MD, PhD, FACP, about the use of circulating tumor DNA (ctDNA) in patients with colorectal cancer (CRC). Dr Kopetz is the deputy chair for Translational Research and a professor in the Department of Gastrointestinal (GI) Medical Oncology in the Division of Cancer Medicine, as well as the leader of the Department of Cancer Center Support Grant in the GI Program, the TRACTION medical director in the Division of Therapeutics Discovery, and the associate vice president for Translational Integration at The University of Texas MD Anderson Cancer Center in Houston, Texas. In our conversation, Dr Kopetz discussed the high positive predictive value of ctDNA assays, which indicate disease presence when positive. He emphasized clinical trials that have shown strong prognostic implications with this type of assay, as well as study findings that demonstrated that ctDNA results could reduce chemotherapy use without compromising efficacy. Additionally, he noted the potential significance of ongoing trials that are exploring the use of ctDNA to guide therapy. Overall, he explained that ctDNA testing is becoming a standard in clinical practice for colorectal cancer.
Host Mikalyn DeFoor, MD Guest interviewee Arianna L. Gianakos, DO, discussing her research article, “Can ChatGPT-4 Diagnose and Treat Like an Orthopaedic Surgeon? Testing Clinical Decision Making and Diagnostic Ability in Soft-Tissue Pathologies of the Foot and Ankle” from the August 15, 2025 issue Article summarized from the August 1, 2025 issue Research article “Patients With Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors Undergoing Total Knee Arthroplasty Are at Increased Odds for a Number of Postoperative Adverse Events But Reduced Risk of Transfusion” Articles summarized from the August 15, 2025 issue Review article “Management and Return to Play of the Elite Athlete for Common Sports-Related Injuries About the Ankle” Follow this link to download these and other articles from the August 1, 2025 issue of JAAOS and the August 15, 2025 issue of JAAOS. The JAAOS Unplugged podcast series is brought to you by the Journal of the American Academy of Orthopaedic Surgeons and the AAOS Resident Assembly.
Do you know the data well enough to answer patients' questions? Data, workflows, and protocols for successful implementation. Credit available for this activity expires: 5/27/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002541?ecd=bdc_podcast_libsyn_mscpedu
In this conversation, Dr. Jennie Berkovich and Dr. Alan Rozanski explore the intricate relationship between stress, optimism, and cardiac health. They discuss the impact of chronic stress on cardiovascular disease, the importance of resilience, and how positive mindsets can promote longevity. The dialogue emphasizes the need for a holistic approach to health that includes behavioral management, mindfulness, and exercise. Dr. Rozanski shares insights on how to effectively communicate these concepts to patients, highlighting the significance of time management in maintaining health. The conversation concludes with a look towards the future of cardiology and patient education.Dr. Alan Rozanski is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Chief Academic Officer, Executive Director of Cardiac Education and Fellowship Training Programs, and Director of Nuclear Cardiology for the Department of Cardiology at Mount Sinai St. Lukes.A graduate of Yale University and the Tufts University School of Medicine, Dr. Rozanski completed his Internal Medicine and Cardiology Fellowship training at Mount Sinai Hospital and a fellowship in Nuclear Medicine at Cedars-Sinai Medical Center in Los Angeles.While at Cedars-Sinai Medical Center, Dr. Rozanski founded a large multi-disciplinary program in Preventive and Rehabilitative Cardiology and initiated research which helped lead to the creation of a new field of Behavioral Cardiology. This led to a prestigious Sabbatical Fellowship from the MacArthur Foundation to study the determinants of health-promoting and health-damaging behaviors alongside many leading behavioral clinicians across the nation.In 1990, Dr. Rozanski joined the cardiology staff of St. Lukes/Roosevelt Hospital (now Mount Sinai St. Lukes and Mount Sinai West Hospitals) where he eventually served as Chief of Cardiology before assuming his current positions.Dr. Rozanski is noted for his unique clinical and academic focus and novel research that uniquely integrates the fields of Preventive Cardiology with Health Psychology and Behavioral Medicine.In addition, Dr. Rozanski is a leading expert in applying Cardiac Imaging for optimal Risk Assessment and Clinical Decision Making among patients who are candidates for cardiac testing due to risk factors or symptoms which are suggesting of heart disease.Dr. Rozanski is the co-author of over 270 peer-reviewed medical articles, book chapters and medical editorials, many of which are considered seminal contributions to the fields of Cardiology and/or Health Psychology._________________________________________________Sponsor the JOWMA Podcast! Email digitalcontent@jowma.orgBecome a JOWMA Member! www.jowma.orgFollow us on Instagram! www.instagram.com/JOWMA_orgFollow us on Twitter!www.twitter.com/JOWMA_medFollow us on Facebook! https://www.facebook.com/JOWMAorgStay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VPA865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until April 26, 2026.Illuminating a Better Path Forward for HR+, HER2- MBC: Bridging the Science and Art of Medicine in Clinical Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Breastcancer.org. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VPA865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until April 26, 2026.Illuminating a Better Path Forward for HR+, HER2- MBC: Bridging the Science and Art of Medicine in Clinical Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Breastcancer.org. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VPA865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until April 26, 2026.Illuminating a Better Path Forward for HR+, HER2- MBC: Bridging the Science and Art of Medicine in Clinical Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Breastcancer.org. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VPA865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until April 26, 2026.Illuminating a Better Path Forward for HR+, HER2- MBC: Bridging the Science and Art of Medicine in Clinical Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Breastcancer.org. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
On this episode of the Sports Medicine Primer Series, host Dr. Zainab Shirazi, MD, continues the conversation with Dr. Dan Cushman, MD, discussing the management of a case of shoulder pain in a 23-year-old backpacker. The goal of this ongoing series is to be an audible study aid for anyone pursuing a career as a sports medicine physician and to prepare them for a sports medicine fellowship. Dr. Cushman is board-certified in both Sports Medicine and Physical Medicine & Rehabilitation, and specializes in the care of musculoskeletal injuries in both athletes & non-athletes, musculoskeletal ultrasound, electrodiagnostics, and endurance sports-specific injuries. He serves as the team physician for the University of Utah Track & Field and Cross-Country teams and is also the team physician for the University of Utah Swimming and Diving teams. Dr. Shirazi is a Sports Medicine Fellow at the University of Colorado. She completed her residency training in Physical Medicine & Rehabilitation (PM&R) at NewYork-Presbyterian Columbia/Cornell, where she served as Chief Resident, and is the current Fellow Chair for AMSSM's Library of Ultrasound Pathology. She is passionate about women's sports medicine and providing specialized care for female athletes. Resources: Best Practices in Sports Medicine: AMSSM and AOASM Case Studies (1st ed) – Case 66 (p. 395): https://amssmstore.com/best-practices-in-sports-medicine-amssm-and-aoasm-case-studies Peripheral Neuropathies of the Upper Extremity | National Fellow Online Lecture Series: https://www.youtube.com/watch?v=vC0XgHvQWXc Unilateral Winged Scapula: Clinical and Electrodiagnostic Experience with 128 cases, With Special Attention to Long Thoracic Nerve Palsy: https://onlinelibrary.wiley.com/doi/full/10.1002/mus.26059 The Natural History of Long Thoracic and Spinal Accessory Neuropathies: https://onlinelibrary.wiley.com/doi/full/10.1002/mus.10068 MR Neurography (MRN) of the Long Thoracic Nerve: Retrospective Review of Clinical Findings and Imaging Results at Our Institution Over 4 Years: https://link.springer.com/article/10.1007/s00256-017-2737-z Ortho Bullets – Scapular Winging: https://www.orthobullets.com/shoulder-and-elbow/3062/scapular-winging Surgical and Clinical Decision Making in Isolated Long Thoracic Nerve Palsy: https://journals.sagepub.com/doi/full/10.1177/1558944717733306 A Comprehensive Analysis of Pectoralis Major Transfer for Long Thoracic Nerve Palsy: https://www.sciencedirect.com/science/article/pii/S1058274614006818
On this episode of the Sports Medicine Primer Series, host Dr. Zainab Shirazi, MD, is joined by Dr. Dan Cushman, MD, to discuss how to manage a case of shoulder pain in a 23-year-old backpacker. The goal of this ongoing series is to be an audible study aid for anyone pursuing a career as a sports medicine physician and to prepare them for a sports medicine fellowship. Dr. Cushman is board-certified in both Sports Medicine and Physical Medicine & Rehabilitation, and specializes in the care of musculoskeletal injuries in both athletes & non-athletes, musculoskeletal ultrasound, electrodiagnostics, and endurance sports-specific injuries. He serves as the team physician for the University of Utah Track & Field and Cross-Country teams and is also the team physician for the University of Utah Swimming and Diving teams. Dr. Shirazi is a Sports Medicine Fellow at the University of Colorado. She completed her residency training in Physical Medicine & Rehabilitation (PM&R) at NewYork-Presbyterian Columbia/Cornell, where she served as Chief Resident, and is the current Fellow Chair for AMSSM's Library of Ultrasound Pathology. She is passionate about women's sports medicine and providing specialized care for female athletes. Resources: Best Practices in Sports Medicine: AMSSM and AOASM Case Studies (1st ed) – Case 66 (p. 395): https://amssmstore.com/best-practices-in-sports-medicine-amssm-and-aoasm-case-studies Peripheral Neuropathies of the Upper Extremity | National Fellow Online Lecture Series: https://www.youtube.com/watch?v=vC0XgHvQWXc Unilateral Winged Scapula: Clinical and Electrodiagnostic Experience with 128 cases, With Special Attention to Long Thoracic Nerve Palsy: https://onlinelibrary.wiley.com/doi/full/10.1002/mus.26059 The Natural History of Long Thoracic and Spinal Accessory Neuropathies: https://onlinelibrary.wiley.com/doi/full/10.1002/mus.10068 MR Neurography (MRN) of the Long Thoracic Nerve: Retrospective Review of Clinical Findings and Imaging Results at Our Institution Over 4 Years: https://link.springer.com/article/10.1007/s00256-017-2737-z Ortho Bullets – Scapular Winging: https://www.orthobullets.com/shoulder-and-elbow/3062/scapular-winging Surgical and Clinical Decision Making in Isolated Long Thoracic Nerve Palsy: https://journals.sagepub.com/doi/full/10.1177/1558944717733306 A Comprehensive Analysis of Pectoralis Major Transfer for Long Thoracic Nerve Palsy: https://www.sciencedirect.com/science/article/pii/S1058274614006818
Sarah Spaulding joins Ethics Talk to discuss her article, coauthored Dr Katherine Fischkoff: “How Should We Understand Regret as a Moral Psychological Experience That Can Influence Clinical Decision-Making?” Recorded January 9, 2024. Read the article for free at JournalOfEthics.org
Dr. E is joined by his new co-host and good friend, Dr. Sean Wells, from Nutritional Physical Therapy. They talk about two ankle cases, both injuries. Dr. E discovered an old classic reset helped both cases WB with significantly less pain. Then they discuss this article by Dr. Tom Michaud, DC and how it has impacted their practice and Clinical Decision Making.Untold Physio Stories is sponsored byComprehend PT- Leave Comprehend PT running in the background or record audio when you have time. The AI based SOAP note generator does the rest! No need for accuracy or exact wording! It's a game changer and will give you more time with your patients! Use code MMT50 to save 50% off your first month. Free trial available at sign up!The Eclectic Approach Network - Check out Dr. E's all new private, non tracking and ad free network for rehab pros! It's free to join, has chat, feed, and all the features of other social networks without the creeping tracking.Check out EDGE Mobility System's Best Sellers - Something for every PT, OT, DC, MT, ATC or Fitness Minded Individual https://edgemobilitysystem.com
Could the key to more effective allergy therapies lie in the nasal microbiome? In this episode of BackTable ENT, Dr. Jennifer Villwock from Kansas University Medical Center discusses the intricacies of treating allergies and sinus issues with hosts Dr. Ashley Agan and Dr. Gopi Shah. --- SYNPOSIS Dr. Villwock begins by highlighting the importance of personalized medicine and the role of the microbiome in immunotherapy. Topics include topical and oral probiotics, the nasal microbiome, intralymphatic immunotherapy, and the significance of accurate allergy testing. Dr. Villwock also shares insights on sublingual and subcutaneous immunotherapy, the future of allergy treatments, and the impact of environmental factors on sinus health. --- TIMESTAMPS 00:00 - Introduction 01:53 - Understanding the Sinus Microbiome 04:34 - The Role of the Microbiome in Health 09:31 - Challenges in Microbiome Research 23:21 - Clinical Decision-Making in Antibiotic Use 25:07 - Exploring Probiotics & Dietary Factors for Sinus Health 30:12 - Immunotherapy and Microbiome 35:47 - Allergy Testing Methods 41:40 - Future Directions in Immunotherapy 44:18 - Conclusion and Final Thoughts --- RESOURCES Jennifer Villwock Profile https://www.kumc.edu/jvillwock.html AAOA 2025 Explorers Course in Allergy and Immunology, Vail, CO. March 27-29, 2025 https://www.aaoallergy.org/education/aaoa-explorers-course-2025/ BackTable+ for ENT https://plus.backtable.com/pages/ent Check out BackTable+ for ENT, our sponsor and new e-learning platform! https://plus.backtable.com/pages/ent
Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826241296412
In this episode of the PFC podcast, Dr. Jim DeCanto, an experienced anesthesiologist, discusses the critical aspects of airway management in emergency situations. He emphasizes the importance of decision-making processes, assessing neurological status, and the necessity of proper planning and preparation for airway interventions. The conversation highlights the challenges faced in both hospital and pre-hospital settings, the significance of having the right equipment, and the need for practitioners to be confident in their skills. Dr. DeCanto shares valuable insights and advice for new practitioners in the field, stressing the importance of thorough assessments and timely interventions to ensure patient safety. Takeaways Airway management is a critical skill for anesthesiologists. Decision-making in emergencies can be complex and requires a plan. Assessing neurological status is crucial before airway interventions. Proper planning and preparation can enhance confidence in emergency situations. Communication with patients, even when unconscious, is important. Practitioners must be ready to act when necessary, as no one else may be available. Understanding the tools and techniques for airway management is essential. Experience and continuous learning are key to improving skills in airway management. Practitioners should not hesitate to perform necessary procedures when indicated. Physical exams and clinical judgment are vital in emergency medicine. Chapters 00:00 Introduction to Airway Management 03:05 Decision-Making in Emergency Situations 12:29 Assessing Neurological Status 20:40 Planning and Preparing for Airway Management 30:50 Clinical Decision-Making in Airway Management 41:21 Advice for New Practitioners Thank you to Delta Development Team for in part, sponsoring this podcast. deltadevteam.com For more content go to www.prolongedfieldcare.org Consider supporting us: patreon.com/ProlongedFieldCareCollective or www.lobocoffeeco.com/product-page/prolonged-field-care
Artificial Intelligence (AI) is revolutionizing healthcare, and oncology is no exception. In this episode of the Exploring AI in Oncology series, Kristin Maloney, MS, BSN, RN, OCN®, a Certified Oncology Nurse and the Clinical Informatics Lead at Mendel AI, speaks with Dr. Waqas Haque on how AI can address some of the biggest challenges in oncology. She shares more about Mendel's innovative platform, which leverages physician-level cognitive capabilities to enhance data process and improve clinical decision making and patient outcomes. Learn more at: https://oncdata.com/mendel-ai-with-kristin-maloney
In this episode of the 3 Pie Squared - ABA Business Leaders podcast, we sit down with Amanda Ralston, founder of Nonbinary Solutions and creator of Knowetic.AI, to discuss how AI is transforming clinical decision-making in the ABA field. Amanda shares her insights on balancing innovation and ethics, building effective clinical tools, and the importance of quality in ABA services. Learn how Knowetic.AI supports clinicians by providing structured pathways to improve patient outcomes and ensure medical necessity. Whether you're a seasoned practitioner or just starting your journey, Amanda's unique perspective and wealth of experience will inspire and inform your practice. Don't miss this conversation about the intersection of technology, clinical expertise, and patient care. Want to learn more about NonBinary Solutions? Check out Knowetic AI! Knowetic.AI, a clinical decision support system helping clinicians streamline their processes and enhance patient outcomes. Learn more at www.knowetic.ai. Starting a practice or looking to enhance your existing one? Download our free startup list here. Access exclusive resources for ABA business leaders by exploring membership options with 3 Pie Squared here.
In this episode of the PFC Podcast, Dennis and Alex discuss the complexities of trauma surgery, particularly focusing on pelvic injuries and the use of pelvic binders. They explore the subjective nature of truth in medical practice, the importance of research and evidence in trauma care, and the anatomy and physiology related to pelvic injuries. The conversation delves into injury patterns, damage control surgery, and the challenges faced in operational environments. They also engage in a debate about the efficacy of pelvic binders, weighing the evidence and risks involved in their use during trauma care. In this conversation, Dennis discusses the critical importance of evidence-based practice in combat medicine, particularly regarding the use of pelvic binders. He emphasizes the need for medical professionals to understand the nuances of pelvic injuries, especially in a combat environment, and how these injuries differ from civilian cases. The discussion also covers the structured approach to prolonged field care, the management of blood transfusions, and the challenges of imaging in trauma assessment. Dennis advocates for clinical decision-making that prioritizes patient safety and effective care, while also acknowledging the emotional weight of these decisions in high-stakes environments. Takeaways Truth is subjective and varies by perception. Disagreement in medical practice can lead to better patient care. Understanding research quality is crucial in medical decisions. Venous bleeding is more common in pelvic injuries than arterial. Damage control surgery involves multiple phases of patient management. Operational environments present unique challenges for trauma care. Pelvic binders are debated in their effectiveness and necessity. Surgical decision-making requires weighing risks and benefits. Evidence-based medicine is essential but often lacking in operational settings. The role of pelvic binders in trauma care remains contentious. Evidence is crucial in medical practice to avoid misinformation. Dismounted IED blasts result in unique injury patterns. Understanding research and statistics is essential for medical professionals. Pelvic binders may not always be beneficial in every injury case. Timely blood transfusions are critical in managing trauma patients. Imaging plays a vital role in assessing pelvic injuries. Clinical decision-making should be based on patient stability and evidence. Prolonged field care requires a structured approach to patient management. Team collaboration is essential in making difficult medical decisions. Continuous education and training are vital for operational medics. Chapters 00:00 Introduction to the Podcast and Guest 02:58 Understanding Trauma Surgery and Pelvic Injuries 06:13 Research and Evidence in Trauma Care 09:06 Anatomy and Physiology of Pelvic Injuries 12:04 Injury Patterns and Their Implications 14:53 Damage Control Surgery and Patient Management 17:48 Operational Environment Challenges 21:03 The Role of Pelvic Binders in Trauma Care 23:52 Debate on Pelvic Binders and Evidence 26:51 Surgical Decision Making in Trauma 29:47 Conclusion and Final Thoughts 45:19 The Importance of Evidence in Medical Practice 52:34 Understanding Pelvic Injuries in Combat 53:59 Prolonged Field Care: A Structured Approach 01:00:03 Managing Blood Transfusions in Critical Care 01:10:06 The Role of Imaging in Trauma Assessment 01:18:00 Clinical Decision-Making in Prolonged Field Care For more content go to www.prolongedfieldcare.org Consider supporting us: patreon.com/ProlongedFieldCareCollective or www.lobocoffeeco.com/product-page/prolonged-field-care
Article - The Impact of MRI-Based Advanced Neuroimaging on Neurooncologists'Clinical Decision-Making in Patients With Posttreatment High-GradeGlioma: A Prospective Survey-Based Study Atefeh Zeinoddini, MD, discusses the AJR article by Dagher et al. exploring the impact of advanced neuroimaging on management decisions after treatment for high-grade glioma, based on surveys of neurooncologists.
Dr. Alan Rozanski is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Chief Academic Officer, Executive Director of Cardiac Education and Fellowship Training Programs, and Director of Nuclear Cardiology for the Department of Cardiology at Mount Sinai St. Lukes. A graduate of Yale University and the Tufts University School of Medicine, Dr. Rozanski completed his Internal Medicine and Cardiology Fellowship training at Mount Sinai Hospital and a fellowship in Nuclear Medicine at Cedars-Sinai Medical Center in Los Angeles. While at Cedars-Sinai Medical Center, Dr. Rozanski founded a large multi-disciplinary program in Preventive and Rehabilitative Cardiology and initiated research which helped lead to the creation of a new field of Behavioral Cardiology. This led to a prestigious Sabbatical Fellowship from the MacArthur Foundation to study the determinants of health-promoting and health-damaging behaviors alongside many leading behavioral clinicians across the nation. In 1990, Dr. Rozanski joined the cardiology staff of St. Lukes/Roosevelt Hospital (now Mount Sinai St. Lukes and Mount Sinai West Hospitals) where he eventually served as Chief of Cardiology before assuming his current positions. Dr. Rozanski is noted for his unique clinical and academic focus and novel research that uniquely integrates the fields of Preventive Cardiology with Health Psychology and Behavioral Medicine. In addition, Dr. Rozanski is a leading expert in applying Cardiac Imaging for optimal Risk Assessment and Clinical Decision Making among patients who are candidates for cardiac testing due to risk factors or symptoms which are suggesting of heart disease. Dr. Rozanski is the co-author of over 270 peer-reviewed medical articles, book chapters and medical editorials, many of which are considered seminal contributions to the fields of Cardiology and/or Health Psychology.
Episode Overview: The integration of augmented intelligence (AI) in clinical settings is revolutionizing healthcare, but it also brings its own set of challenges. In this episode, Maria Granzotti, MD, MBA, CPE, CHCQM, FABQAURP, FACHE, dives into the current landscape of clinical augmented intelligence (CAI). She defines CAI, discusses its primary purposes and benefits, and examines its potential to reduce healthcare costs. Key Questions: • How is CAI different from traditional AI? • What does "human in the loop" mean in the context of CAI? • Is now the right time for CAI? Episode Highlights: • Technology Integration: Discover how CAI seamlessly integrates into existing clinical workflows, enhancing the tools physicians already use. • Quality Improvement: Learn from real-world examples about how CAI supports quality and safety initiatives in healthcare. • Healthcare Delivery: Explore how CAI can revolutionize healthcare delivery by reducing administrative burdens and shifting the focus back to patient care. About the Expert: Maria Granzotti, MD, MBA, CPE, CHCQM, FABQAURP, FACHE, is the chief medical advisor and clinical strategist for Digital Strategies Group, LLC. With 15 years of experience in healthcare executive leadership and 20 years in emergency medicine, she has a proven track record of delivering value and prioritizing patient safety. Granzotti has led quality and safety initiatives at a multihospital system in Texas and has played a pivotal role in shaping strategies for over 150 hospitals across the country. The Big Picture: CAI is creating new possibilities for patients and physicians, driving advancements in technology and quality in healthcare. Learn more about the American Association for Physician Leadership.
Ambivalence is a tough concept when it comes to decision-making. On the one hand, when people have ambivalence but haven't explored why they are ambivalent, they are prone to bad, value-incongruent decisions. On the other hand, acknowledging and exploring ambivalence may lead to better, more ethical, and less biased decisions. On today's podcast, Joshua Briscoe, Bryanna Moore, Jennifer Blumenthal-Barby, and Olubukunola Dwyer discuss the challenges of ambivalence and ways to address them. This podcast was initially sparked by Josh's “Note From a Family Meeting” Substack post titled “Ambivalence in Clinical Decision-Making,” which discussed Bryanna's and Jenny's 2022 article titled “Two Minds, One Patient: Clearing up Confusion About Ambivalence." Bryanna's and Jenny's article is particularly unique as it discusses these “ambivalent-related phenomena” and that these different kinds of “ambivalence” may call for different approaches with patients, surrogates (and health care providers): In addition to defining these “ambivalent related phenomena” we ask our guests to cover some of these topics: Is ambivalence good, bad, or just a normal part of decision-making? Does being ambivalent mean you don't care about the decision? What should we be more worried about in decision-making, ambivalence or the lack thereof? The concern about resolving ambivalence too quickly, as it might rush past important work that needs to be done to make a good decision. What about ambivalence on the part of the provider? How should we think about that? How do you resolve ambivalence? Lastly, the one takeaway point from this podcast is that the next time I see ambiguity (or have it myself), I should ask the following question: “I see you are struggling with this decision. Tell me how you are feeling about it.”
Hey friends! Scot Morrison is a physical therapist, strength coach, and educator who currently works in special operations. Scot has a special interest in clinical decision making and managing uncertainty in clinical practice. We also cover the importance of understanding what you're actually measuring when you perform objective testing. Finally, we wrap up the conversation talking about the relationship between constraints and exercise dosage. Enjoy! CALU FB Community: https://www.facebook.com/groups/calucommunity/
The field of oncology treatments is advancing very fast with innovative therapies and approaches on the market every day. It can get very tricky to support these therapies from an IT perspective, which is what you will hear more about in this discussion. I spoke with Anish Patankar, SVP and GM of Elekta's Oncology Software Solutions, and we discusses: How to go about the US hospital market, Development in software for oncology treatments, Challenges in scaling healthcare IT software across markets. Newsletter: https://fodh.substack.com/ www.facesofdigitalhealth.com Show notes: [00:00:00] Introduction to Elekta [00:02:00] Elekta's Global Presence [00:04:00] US Market Focus [00:06:00] Growth in Developing Countries [00:08:00] Segmentation and Technology Adoption in the US [00:10:00] Untapped Needs and Opportunities in the US [00:12:00] Elekta's Use of AI [00:14:00] Patient Feedback and Clinical Decision Making [00:18:00] Navigating Legacy Software in Healthcare IT [00:20:00] Modernization and Customer Satisfaction [00:22:00] Global Standardization and Regulation Challenges [00:24:00] Interoperability and Open Ecosystem [00:26:00] Future of Oncology Market Development: the interplay between medications and radiation, and the potential of theranostics. [00:28:00] Exciting Technologies in Healthcare Beyond Oncology: personalized healthcare, digital twins [00:30:00] Cautions for the Future: The critical debate on the balance between innovation speed and safety, particularly with generative AI.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KBV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 17, 2025.Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).Faculty/PlannerKomal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.Faculty/PlannerProfessor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KBV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 17, 2025.Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).Faculty/PlannerKomal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.Faculty/PlannerProfessor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Welcome to Season 5 of the podcast. In this first episode, It's my great pleasure to introduce Professor Jill Klein. In addition to numerous other hats and talents Jill is Professor of Marketing at Melbourne Business School and Professorial Fellow in Medical Education at Melbourne Medical School. Jill received her Ph.D. in Social Psychology from the University of Michigan in 1990 and since then has taught at top universities and business school around the world. She joined the faculty at Kellogg Graduate School of Management, Northwestern University in 1990, and the faculty at INSEAD in 1997.She has also been a visiting scholar at Duke University, Helsinki School of Business and Economics, and University of Texas at Austin. She joined Melbourne Business School in 2009, and Melbourne Medical School in 2015. Jill teaches Resilience and Well-Being, Managerial Judgment, Clinical Decision Making, and Leadership. Her research interests are in resilience and well-being, decision making, business ethics and ethical consumption. She has published widely, including in the British Medical Journal, Medical Education, Management Science, Journal of Consumer Researchand Harvard Business Review. She authored the book, We Got the Water: Tracing My Family's Path Through Auschwitz, and is currently writing (with Dr. Vinita Rane), Thriving in Medial School, a well-being book for medical students. She often appears in the media, and has had pieces published in The Guardian, Australian Financial Review, The Age and Huffington Post. I had the great privilege of being taught Managerial Judgement by Jill at the Melbourne Business School in late 2023 and was struck by the importance of her work and applied expertise in healthcare. This work is very much aligned with this podcast mission and listenership. In this conversation we hear more about Jill's early career experiences and how these may have contributed to her subsequent trajectory, research interests and teaching mission. I was particularly keen to explore her work around clinical error and growth mindset. Jill fields some tough questions from me on the topic of resilience in healthcare and we are treated to a taster of her upcoming book "Thriving in Medical School". I anticipate a successful "Thriving In..." book series to come. Thank you Professor Klein, I very much hope there will be part 2 to this episode at a later date.This episode of dedicated to incredible life and memory of Gene Klein, Jill's dear and beloved best friend and father.Links/References/ Contacts:https://mbs.edu/faculty-and-research/faculty/jill-kleinhttps://www.amazon.com.au/We-Got-Water-Tracing-Auschwitz/dp/0615806961 Growth mindset YouTube series for medical studentshttps://youtu.be/YdmlTf8zTYQ?si=tpUvLC56C2fXLHeMJill's Recommendations:https://ig.ft.com/sites/business-book-award/books/2023/winner/right-kind-of-wrong-by-amy-edmondson/The Mind Full Medic Podcast is proudly sponsored by the MBA NSW-ACT Find out more about their service or donate today at www.mbansw.org.auDisclaimer: The content in this podcast is not intended to constitute or be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your doctor or other qualified health care professional. Moreover views expressed here are our own and do not necessarily reflect those of our employers or other official organisations.
CardioNerds co-founder Dr. Amit Goyal, series co-chair Dr. Colin Blumenthal, and episode lead Dr. Anushka Tandon to discuss pharmacologic anticoagulation options in atrial fibrillation with Drs. Ashley Lochman and Chris Domenico. The case-based review helps clarify some key concepts, such as when warfarin is preferred for anticoagulation, who may be a good DOAC (direct-acting oral anticoagulant) candidate, how to choose an appropriate DOAC agent, and how to manage anticoagulation therapy in patients already on antiplatelet therapies. Notes were drafted by Dr. Anushka Tandon. The episode audio was edited by student Dr. Shivani Reddy. This CardioNerds Atrial Fibrillation series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Kelly Arps and Dr. Colin Blumenthal. This episode was planned and recorded prior to the release of the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Please refer to this guideline document for the most updated recommendations. We have collaborated with VCU Health to provide CME. Claim free CME here! CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Anticoagulation Pharmacology Avoid potentially fatal errors with this terminology tip for correctly referencing non-warfarin oral anticoagulant agents: it's DOAC (like, please DO use AntiCoagulation), not NOAC (imagine someone interpreting that as “NO AntiCoagulation for this patient” at discharge – yikes)! Sometimes, an oldie really is a goodie – warfarin is recommended over DOACs for patients with mechanical heart valves, moderate-to-severe mitral stenosis, anti-phospholipid antibody syndrome (APLS), left ventricular (LV) thrombus, higher INR goals, or DOAC failure. Patient preference and medication costs should also be considered – at the end of the day, “the best drug is the drug that a patient is willing to take!” Standard-dose rivaroxaban or apixaban may be considered for use in patients weighing >120kg or with BMI >40; use of other DOACs should be limited to pts weighing =/< 120kg or with BMI =/< 40. The pharmacists involved in this podcast promise they don't have stock in apixaban! It just often happens to be the preferred DOAC option in certain scenarios – think patients with severe renal impairment (including ESRD) or with an increased risk for bleeding events (including older adults, those with a history of GI bleed, etc). In general, dual therapy (DOAC or warfarin + P2Y12 inhibitor) is non-inferior to triple therapy (oral anticoagulant + P2Y12 inhibitor + aspirin) at preventing thrombotic events but is associated with a lower risk of bleeding events. Most patients can be transitioned to dual therapy after 7-30 days on triple therapy post-percutaneous coronary intervention. What's that on the horizon? Factor XI inhibitors may become the breakout stars of anticoagulation – multiple investigational agents are being studied for their potential to reduce thrombotic risk without significantly increasing bleeding risk in patients with indications for anticoagulation therapy…at least that's the theorize hope. Watch this space! Notes - Anticoagulation Pharmacology In which cases is warfarin preferred over DOACs in patients with atrial fibrillation? Long-term anticoagulation with warfarin is indicated in patients with atrial fibrillation and either a mechanical valve or moderate-to-severe mitral stenosis (i.e., valvular atrial fibrillation as defined in the 2019 AHA/ACC/HRS guidelines on atrial fibrillation [1]). The REALIGN trial [2] showed increased rates of thromboembolic and bleeding complications with dabigatran vs.
Health Affairs' Editor-in-Chief Alan Weil interviews Tina Hernandez-Boussard of Stanford University on her recent paper exploring ways that we can promote equity in clinical decision-making and how to dismantle race-based medicine.Order the October 2023 issue of Health Affairs.Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone.
Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, moderated by Dr Mascarenhas, including the following topics: Introduction (0:00) Clinical Decision-Making for Patients with Myelofibrosis (MF) — Dr Bose (2:27) Management of MF in Special Patient Populations — Dr Mascarenhas (19:26) Future Directions in the Management of MF — Dr Kuykendall (48:09) CME information and select publications
Clinical decision making tools for ruling in and out the need for medical imaging following foot and ankle injuries.
Dereck Paul, MD is a cofounder and the CEO of Glass Health, an AI-powered medical knowledge management and clinical decision-making platform that helps clinicians provide better patient care. Previously, he was an internal medicine resident at Brigham and Women's Hospital, Harvard Medical School and a medical student at the UCSF School of Medicine. Host: David Wu Twitter: @davidjhwu Audio Producer + Video Editor + Art: Saurin Kantesaria Instagram: saorange314 Social Media: Nikhil Kapur Time Stamps: 01:13 - From music major to med school to making a startup 06:30 - Poor healthcare technology = physician burnout, the motivation for building Glass Health 09:15 - Glass Notebook - "Notion for doctors" 11:24 - Building a startup in the era of Chat-GPT 13:50 - What doctors need in an AI-assisted diagnosis software 19:15 - Transition towards a more AI oriented technology - Glass AI 23:00 - How does Glass AI make accurate diagnoses? 28:40 - Why doctors need to be involved in building clinical AI products 30:50 - Practical usage of Glass AI in the clinic 33:04 - Why Glass AI will be more trustworthy than Chat-GPT in writing clinical notes 37:43 - Why LLMs don't need to be perfect for use in the clinic 40:28 - Ethical implications of Glass AI and similar products 45:34 - Should we disclose when we use AI to write a clinical note? 49:13 - What do you think the future of AI in medicine will look like in 10-20 years? 52:30 - What brings you joy? What gives your life meaning? 56:10 - Would you ever go back to being a musician?
For years Advisory Board has been researching how technology and macro-economic forces are shaping clinical decision-making, and recent advances in large language models and AI have the potential to make an impact like we've never seen before. In this episode, guest host and Advisory Board life sciences expert Soloman Banjo invites Advisory Board expert Amanda Okaka and Optum's Senior Vice President of Clinical Innovation Dr. Kevin Larson to discuss the technologies that will change clinical decision-making in the next decade, its implications, and what organizations should be thinking about as they integrate them into clinical workflows. Links: How clinicians will use evidence in 2032 5 takeaways from our expert panel on technology's role in the future of clinical decision-making The future of clinical decision-making at the institutional level Learn more about Advisory Board's upcoming webinar on key innovations in cancer care for patients by visiting https://www.advisory.com/resources/events
© 2020-2026 Ivy Podcast Discovery LLC
